Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis

Journal of Neurochemistry

Volumn 95, Issue 5, 2005, Pages 1461-1471

  Ranganathan, Srikanth ^a   Williams, Eric ^b   Ganchev, Philip ^b   Gopalakrishnan, Vanathi ^b   Lacomis, David ^a   Urbinelli, Leo ^c   Newhall, Kristyn ^c   Cudkowicz, Merit E ^c   Brown Jr , Robert H ^c   Bowser, Robert ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Amyotrophic lateral sclerosis; Cerebrospinal fluid; Mass spectrometry; Proteomics

Indexed keywords

BIOLOGICAL MARKER; BRAIN PROTEIN; CYSTATIN C; NEUROENDOCRINE PROTEIN 7B2; PREALBUMIN; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ADULT; ALGORITHM; AMYOTROPHIC LATERAL SCLEROSIS; ANTIGEN BINDING; ARTICLE; CARBOXY TERMINAL SEQUENCE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; HUMAN; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MOTOR NERVE; NERVE DEGENERATION; PATHOGENESIS; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; STATISTICAL SIGNIFICANCE; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; ALGORITHMS; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; CYSTATINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JUNIPERUS; MALE; MIDDLE AGED; MOTOR NEURONS; NEUROENDOCRINE SECRETORY PROTEIN 7B2; PREALBUMIN; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; SPINAL CORD;

EID: 28844432511     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2005.03478.x     Document Type: Article

References (52)

1. Allen S., Heath P. R., Kirby J., Wharton S. B., Cookson M. R., Menzies F. M., Banks R. E. and Shaw P. J. (2003) Analysis of the cytosoloic proteome in a cell-culture model of familial amyotrophic lateral sclerosis reveals alterations to the proteasome, antioxidant defences and nitric oxide synthetic pathways. J. Biol. Chem. 278, 6371-6383.
2. Brooks B. R. (1999) Diagnostic dilemmas in amyotrophic lateral sclerosis. J. Neurol. Sci. 165, S1-S9.
3. Bruijn L. I., Miller T. M. and Cleveland D. W. (2004) Unraveling the mechanisms involved in motor neuron degeneration in ALS. Annu. Rev. Neurosci. 27, 723-749.
4. Carrette O., Demalte I., Scherl A., Yalkinoglu O., Corthals G., Burkhard P., Hochstrasser D. F. and Sanchez J. C. (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3, 1486-1494.
5. Chaudhuri B. (1995) The neuroendocrine protein 7B2 acts as a molecular chaperone in the in vitro folding of human insulin-like growth factor-1 secreted from yeast. Biochem. Biophys. Res. Commun. 211, 417-425.
6. Choe L. H., Dutt M. J., Relkin N. and Lee K. H. (2002) Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease. Electrophoresis 23, 2247-2251.
7. Cleveland D. W. and Rothstein J. (2001) From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2, 806-819.
8. Coria F. and Rubio I. (1996) Cerebral amyloid angiopathies. Neuropathol Appl. Neurobiol. 22, 216-227.
9. Cutler R. G., Pedersen W. A., Camandola S., Rothstein J. D. and Mattson M. P. (2002) Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann. Neurol. 52, 448-457.
10. Davidsson P., Ekman R. and Blennow K. (1997) A new procedure for detecting brain-specific proteins in cerebrospinal fluid. J. Neural Transm. 104, 711-720.
11. Deng A. (2001) Elevation of cystatin C in susceptible neurons in Alzheimer's disease. Am. J. Pathol. 159, 1061-1068.
12. Dickson D. W., Crystal H. A., Mattiace L. A., Masur D. M., Blau A. D., Davies P., Yen S. H. and Aronson M. K. (1992) Identification of normal and pathological aging in prospectively studied nondemented elderly humans. Neurobiol. Aging 13, 179-189.
13. Dumont D., Noben J.-P., Raus J., Stinissen P. and Robben J. (2004) Proteomic analysis of cerebrospinal fluid from multiple sclerosis patients. Proteomics 4, 2117-2124.
14. Feigenbaum E. A. and Buchanan B. G. (1993) Dendral and meta-dendral - roots of knowledge systems and expert system applications. Artificial Intelligence 59, 233-240.
15. Gonatas N. K. (1992) Fragmentation of the Golgi apparatus of motor neurons in amyotrophic lateral sclerosis. Am. J. Pathol. 140, 731-737.
16. Gopalakrishnan V., Williams E., Ranganathan S., Bowser R., Cudkowicz M., Novelli M., Lattanzi W., Gambotto A. and Day B. W. (2004) Proteomic data mining challenges in identification of disease-specific biomarkers from variable resolution mass spectra, in Proceedings of SIAM Data Mining (Obradovic, Z. and Komorowski, J., eds), pp. 1-10. SIAM, Philadelplia.
17. Gurney M. E., Pu H., Chiu A. Y. et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264, 1772-1775.
18. Hwang J. R. and Lindberg I. (2001) Inactivation of the 7B2 inhibitory CT peptide depends on a functional furin cleavage site. J. Neurochem. 79, 437-444.
19. Jackson C. E. and Bryan W. W. (1998) Amyotrophic lateral sclerosis. Semin. Neurol. 18, 27-39.
20. Jacobsson J., Jonsson P. A., Andersen P. M., Forsgren L. and Marklund S. L. (2001) Superoxide dismutase in CSF from amyotrophic lateral sclerosis patients with and without CuZn-superoxide dismutase mutations. Brain 124, 1461-1466.
21. Kalso E. (2004) Biomarkers for pain. Pain 107, 199-201.
22. Kriz J., Cowing G. and Julien J.-P. (2003) Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann. Neurol. 53, 429-436.
23. Levy E. (2001) Codeposition of cystatin C with amyloid-beta protein in the brain of Alzheimer disease patients. J. Neuropathol. Exp. Neurol. 60, 94-104.
24. Luo X., Carlson K. A., Wojna V., Mayo R., Biskup T. M., Stoner J., Anderson J., Gendelman H. E. and Melendez L. M. (2003) Macrophage proteomic fingerprinting predicts HIV-1-associated cognitive impairment. Neurology 60, 1931-1937.
25. Marcinkiewicz M. (1993) Expression of neuroendocrine secretory protein 7B2 mRNA in the mouse and rat pituitary gland. Neuroendocrinology 58, 86-93.
26. Marcinkiewicz M., Touraine P. and Chretien M. (1994) Pan-neuronal mRNA expression of the secretory polypeptide 7B2. Neurosci. Lett. 177, 91-94.
27. Monaco H. L. (2000) The transthyretin-retinol-binding protein complex. Biochim. Biophys. Acta 1482, 65-72.
28. Okamoto K. (1993) Bunina bodies in amyotrophic lateral sclerosis immunostained with rabbit anti-cystatin C serum. Neurosci. Lett. 162, 125-128.
29. Perry T. L., Krieger C., Hansen S. and Eisen A. (1990) Amyotrophic lateral sclerosis: amino acid levels in plasma and cerebrospinal fluid. Ann. Neurol. 28, 12-17.
30. Power D. M. (2000) Evolution of the thyroid hormone-binding protein, transthyretin. Gen. Comp. Endocrinol. 119, 241-255.
31. Provost F. and Buchanan B. (1995) Inductive Policy: The pragmatics of bias selection. Machine Learning 20, 35-61.
32. Ramstrom M., Ivonin I., Johansson A., Askmark H., Markides K. E., Zubarev R., Hakansson P., Aquilonius S.-M. and Bergquist J. (2005) Cerebrospinal fluid protein patterns in neurodegenerative disease revealed by liquid chromatography-Fourier transform ion cyclotron resonance mass spectrometry. Proteomics 4, 4010-4018.
33. Ranganathan S. and Bowser R. (2003) Alterations in G1 to S phase cell-cycle regulators during amyotrophic lateral sclerosis. Am. J. Pathol. 162, 823-835.
34. Riviere M., Meininger V., Zeisser P. and Munsat T. (1998) An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch. Neurol. 55, 526-528.
35. Rohlff C. (2000) Proteomics in molecular medicine: applications in central nervous systems disorders. Electrophoresis 21, 1227-1234.
36. Rosen D. R., Siddique T., Patterson D. et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62.
37. Sanchez J. C. (2004) Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 4, 2229-2233.
38. Saraiva M. J. (2001) Transthyretin mutations in hyperthyroxinemia and amyloid diseases. Hum. Mutat. 17, 493-503.
39. Schreiber G. (2002) The evolution of transthyretin synthesis in the choroid plexus. Clin. Chem. Lab. Med. 40, 1200-1210.
40. Seilhean D. (2004) Amyotrophic lateral sclerosis with neuronal intranuclear protein inclusions. Acta Neuropathol. 108, 81-87.
41. Serot J. M., Christmann D., Dubost T. and Couturier M. (1997) Cerebrospinal fluid transthyretin: aging and late onset Alzheimer's disease. J. Neurol Neurosurg. Psychiatry 63, 506-508.
42. Simpson E. P., Henry Y. K., Henkel J. S., Smith R. G. and Appel S. H. (2004) Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 62, 1758-1765.
43. Smith R. G., Henry Y. K., Mattson M. P. and Appel S. H. (1998) Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Ann. Neurol. 44, 696-699.
44. Stein T. D., Anders N. J., DeCarli C., Chan S. L., Mattson M. P. and Johnson J. A. (2004) Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APPsw mice resulting in tau phosphorylation and loss of hippocampal neurons: Support for the amyloid hypothesis. J. Neurosci. 24, 7707-7717.
45. Strey C. W., Spellman D., Stieber A., Gonatas J. O., Wang X., Lambris J. D. and Gonatas N. K. (2004) Dysregulation of stathmin, a microtubule- destabilizing protein, and up-regulation of Hsp25, Hsp27, and the antioxidant peroxiredoxin 6 in a mouse model of familial amyotrophic lateral sclerosis. Am. J. Pathol. 165, 1701-1718.
46. Subramaniam J. R., Lyons W. E., Liu J., Bartnikas T. B., Rothstein J., Price D. L., Cleveland D. W., Gitlin J. D. and Wong P. C. (2002) Mutant SOD1 causes motor neuron disease independent of copper chaper-one-mediated copper loading. Nat. Neurosci. 5, 301-307.
47. Tsuji T., Shiozaki A., Kohno R., Yoshizato K. and Shimohama S. (2002) Proteomic profiling and neurodegeneration in Alzheimer's disease. Neurochem. Res. 27, 1245-1253.
48. Van Westerlaak M. G., Joosten E. A., Gribnau A. A., Cools A. R. and Bar P. R. (2001) Chronic mitochondrial inhibition induces glutamate-mediated conrticomotoneuron death in an organotypic culture model. Exp. Neurol. 167, 393-400.
49. van Welsem M. E. (2002) The relationship between Bunina bodies, skein-like inclusions and neuronal loss in amyotrophic lateral sclerosis. Acta Neuropathol. 103, 583-589.
50. Wiederkehr F., Wacker M. and Vonderschmitt D. J. (1989) Analysis of immune complexes of cerebrospinal fluid by two-dimensional gel electrophoresis. Electrophoresis 10, 473-479.
51. Wong P. C., Pardo C. A., Borchelt D. R., Lee M. K., Copeland N. G., Jenkins N. A., Sisodia S. S., Cleveland D. W. and Price D. L. (1995) An adverse properly of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14, 1105-1116.
52. Zhu X. (1996) Internal cleavage of the inhibitory 7B2 carboxyl-terminal peptide by PC2: a potential mechanism for its inactivation. Proc. Natl Acad. Sci. USA 93, 4919-924.